A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis.
A danazol-loaded intrauterine device (IUD) containing 300-400 mg of danazol was inserted for 6 months in a group of women (n = 18) (median age 36.6 years; age range: 30 to 46 years) with a histologic diagnosis of endometriosis, referred for recurrent pelvic pain. Dysmenorrhea, dyspareunia, and pelvic pain significantly decreased after the first month, with a persistent effect during the 6 months of IUD insertion. These results show that a danazol-loaded IUD is an effective conservative therapy for patients with endometriosis-related pelvic pain.
Cobellis
Luigi
L
Razzi
Sandro
S
Fava
Antonio
A
Severi
Filiberto M
FM
Igarashi
Masao
M
Petraglia
Felice
F
D000328:Adult; D003613:Danazol / Q000008:administration & dosage*; D004412:Dysmenorrhea / Q000188:drug therapy* / Q000209:etiology; D004414:Dyspareunia / Q000188:drug therapy* / Q000209:etiology; D004715:Endometriosis / Q000150:complications*; D004965:Estrogen Antagonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D008875:Middle Aged; D016896:Treatment Outcome
D004965:Estrogen Antagonists; D003613:Danazol